MedPath

Behavioral side effects and the family burden in children and adolescents with epilepsy receiving antiepileptic drugs

Recruiting
Conditions
G40
Epilepsy
Registration Number
DRKS00031703
Lead Sponsor
niversitätsmedizin Halle Universitätsklinik und Poliklinik für Pädiatrie I
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Children and adolescents with newly diagnosed epilepsy who require drug therapy to control seizures.

Exclusion Criteria

Taking other medications that have psychiatric disorders listed as a side effect.
Patients whose parent is not able to fill out the questionnaire independently (e.g. due to insufficient language skills).

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recording behavioral problems in children and adolescents with new-onset epilepsy using the German version of the standardized parent questionnaire Child Behavior Checklist” (CBCL) [Plück,Döpfner et al.] and monitoring how these develop under the respective drug therapy for seizure control. <br>The first survey takes place directly at the doctor's appointment after the epileptic seizure and before taking the antiepileptic medication for the first time. The second and third survey points take place approximately 6 weeks and 3 months after the start of drug therapy.
Secondary Outcome Measures
NameTimeMethod
Recording of predictors, which promote behaviorial side effects under therapy with antiepileptic drugs. The variables include the socioeconomic status of the families and the family burden of the childrens illness, which was measured using the shortened and the standardized version of the german verson of the Impact on Family Scale (FaBel) by Ravens-Sieberer et al. Furthermore added by exploratory questions. The socioeconomic status is determined immediately at the doctor's presentation after the epileptic seizure and before the first intake of antiepileptic medication. The family's burden of the child's illness is only assessed after 6 weeks and 3 months after the start of drug therapy.
© Copyright 2025. All Rights Reserved by MedPath